Hutchison China Meditech Limited Results of AGM (9828W)

TIDMHCM

RNS Number : 9828W

Hutchison China Meditech Limited

24 April 2019

Results of Annual General Meeting

London: Wednesday, April 24, 2019: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting ("AGM") held on April 24, 2019 were duly passed. The poll results of the resolutions were as follows:

 
                                                                       Number of Votes (%)* 
 
   Resolutions                                                   For          Against       Withheld(#) 
        To consider and adopt the audited 
         financial statements and the reports 
         of the directors and independent 
         auditor for the year ended 31 December 
 1       2018.                                               60,078,559      233,957          1,332 
                                                             (99.61209%)    (0.38791%) 
 
 2(A)   To re-elect Mr Simon To as a director.               55,000,510     2,112,677       3,200,661 
                                                             (96.30089%)    (3.69911%) 
 
        To re-elect Mr Christian Hogg as 
 2(B)    a director.                                         60,226,266       86,649           933 
                                                             (99.85633%)    (0.14367%) 
 
        To re-elect Mr Johnny Cheng as a 
 2(C)    director.                                           60,197,095      116,287           466 
                                                             (99.80720%)    (0.19280%) 
 
 2(D)   To re-elect Dr Weiguo Su as a director.              60,200,656      112,989           203 
                                                             (99.81266%)    (0.18734%) 
 
 2(E)   To re-elect Dr Dan Eldar as a director.              60,105,167      208,198           483 
                                                             (99.65481%)    (0.34519%) 
 
 2(F)   To re-elect Ms Edith Shih as a director.             60,089,527      222,933          1,388 
                                                             (99.63037%)    (0.36963%) 
 
        To re-elect Mr Paul Carter as a 
 2(G)    director.                                           60,309,174       3,701            973 
                                                             (99.99386%)    (0.00614%) 
 
        To re-elect Dr Karen Ferrante as 
 2(H)    a director.                                         60,310,246       3,336            266 
                                                             (99.99447%)    (0.00553%) 
 
        To re-elect Mr Graeme Jack as a 
 2(I)    director.                                           60,216,995       96,337           516 
                                                             (99.84027%)    (0.15973%) 
 
        To re-elect Professor Tony Mok as 
 2(J)    a director.                                         60,313,056        359             433 
                                                             (99.99940%)    (0.00060%) 
 
        To re-appoint PricewaterhouseCoopers 
         as the auditor of the Company and 
         authorise the board of directors 
 3       to fix the auditor's remuneration.                  60,309,718       3,922            208 
                                                             (99.99350%)    (0.00650%) 
 
        To increase the authorised share 
 4       capital.                                            58,172,894     2,140,527          427 
                                                             (96.45099%)    (3.54901%) 
 
                                  To grant a general 
                                   mandate to the 
                                   directors of the 
        Ordinary Resolution        Company to issue 
 5       No. 5(A)             :    additional shares.        58,378,604     1,934,441          803 
                                                             (96.79267%)    (3.20733%) 
 
                                  To disapply pre-emption 
        Special Resolution         rights (general 
         No. 5(B)             :    power).                   59,336,430      973,921          3,497 
                                                             (98.38515%)    (1.61485%) 
 
                                  To disapply pre-emption 
                                   rights (in connection 
        Special Resolution         with an equity 
         No. 5(C)             :    raise).                   48,922,239     11,387,728        3,881 
                                                             (81.11800%)    (18.88200%) 
 
                                  To grant a general 
                                   mandate to the 
                                   directors of the 
                                   Company to repurchase 
        Ordinary Resolution        shares of the 
         No. 5(D)             :    Company.                  60,312,021       1,694            133 
                                                             (99.99719%)    (0.00281%) 
 

* Percentages rounded to 5 decimal places

(#) A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for and against a resolution.

As at the date of the AGM, the number of issued shares of Chi-Med was 66,657,745, which was the total number of shares entitling the holders to attend and vote on the ordinary resolutions and special resolutions proposed at the AGM.

About Chi-Med

Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 420 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med's Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market, Chi-Med is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President, Corporate Finance & Development      [phone] 
  Annie Cheng, Vice President, Corporate Finance & Development          [phone] 
  David Dible, Citigate Dewe Rogerson                                   [phone] (Mobile) 
                                                                        [e-mail] 
  Xuan Yang, Solebury Trout                                             [phone] (Mobile) 
                                                                         [e-mail] 
 
Media Enquiries 
  UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson                [phone] (Mobile) 
                                                                         [e-mail] 
  Americas - Brad Miles, Solebury Trout                                 [phone] (Mobile) 
                                                                         [e-mail] 
  Hong Kong & Asia ex-China          - Joseph Chi Lo, Brunswick         [phone] (Mobile) 
                                                                         [e-mail] 
                                     - Zhou Yi, Brunswick               [phone] (Mobile) 
                                                                         [e-mail] 
  Mainland China - Sam Shen, Edelman                                    [phone] (Mobile) 
                                                                         [e-mail] 
 
Nominated Advisor 
  Richard Gray / Atholl Tweedie, Panmure Gordon (UK) Limited            [phone] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RAGLZLFLKZFEBBB

(END) Dow Jones Newswires

April 24, 2019 08:54 ET (12:54 GMT)